Sign in
MLYS Stock Price, Chart, Stats & News
Mineralys Therapeutics, Inc.
Save
Mineralys Therapeutics, Inc. (MLYS) does not currently pay a dividend.
2.34B
Market cap
–
Current P/E
–
Forward P/E
MLYS chart
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | – |
ROA | -23.37% |
ROE | -32.94% |
D/E | – |
Interest coverage ratio | – |
MLYS valuation
P/E | – |
P/S | – |
P/B | 2.95x |
P/CF | -13.39x |
P/FCF | -11.02x |
P/OCF | -13.39x |
PEG | -0.63x |
EV multiple | -10.48x |
About
Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing medicines to target diseases driven by abnormally elevated aldosterone. Its clinical-stage product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that are initially developing for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone, including hypertension and chronic kidney disease. The company was founded by Brian Taylor Slingsby on May 31, 2019 and is headquartered in Radnor, PA.
Similar securities
Based on sector and market capitalization
Report issue